192 related articles for article (PubMed ID: 12629069)
1. Clinical review 155: Pheochromocytoma in Von Hippel-Lindau disease.
Hes FJ; Höppener JW; Lips CJ
J Clin Endocrinol Metab; 2003 Mar; 88(3):969-74. PubMed ID: 12629069
[No Abstract] [Full Text] [Related]
2. von Hippel-Lindau disease: genetic and clinical observations.
Iliopoulos O
Front Horm Res; 2001; 28():131-66. PubMed ID: 11443850
[No Abstract] [Full Text] [Related]
3. A family with von Hippel-Lindau disease revealed by pheochromocytoma.
Tomita N; Moriguchi A; Yamasaki K; Taniyama Y; Kotani N; Hashiya N; Yoshida M; Yao M; Higaki J; Ogihara T
Hypertens Res; 2001 Jul; 24(4):445-50. PubMed ID: 11510758
[TBL] [Abstract][Full Text] [Related]
4. Pheochromocytoma and clear-cell renal carcinoma in a child with von Hippel-Lindau disease: a patient report.
Ferragut J; Caimari M; Rituerto B; Gómez-Rivas B; Herrera M; Alonso F
J Pediatr Endocrinol Metab; 1999; 12(4):579-82. PubMed ID: 10417977
[TBL] [Abstract][Full Text] [Related]
5. [Von Hippel-Lindau disease].
Takahashi K; Iida K; Chihara K
Nihon Rinsho; 2006 Sep; Suppl 3():351-4. PubMed ID: 17022562
[No Abstract] [Full Text] [Related]
6. Renal cell carcinoma- and pheochromocytoma-specific altered gene expression profiles in VHL mutant clones.
Tsuchiya MI; Okuda H; Takaki Y; Baba M; Hirai S; Ohno S; Shuin T
Oncol Rep; 2005 Jun; 13(6):1033-41. PubMed ID: 15870918
[TBL] [Abstract][Full Text] [Related]
7. The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.
Barry RE; Krek W
Trends Mol Med; 2004 Sep; 10(9):466-72. PubMed ID: 15350900
[No Abstract] [Full Text] [Related]
8. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
9. Pheochromocytoma as the first manifestation of von Hippel-Lindau disease.
Richard S; Beigelman C; Duclos JM; Fendler JP; Plauchu H; Plouin PF; Resche F; Schlumberger M; Vermesse B; Proye C
Surgery; 1994 Dec; 116(6):1076-81. PubMed ID: 7985090
[TBL] [Abstract][Full Text] [Related]
10. The von Hippel-Lindau tumor suppressor gene.
Kondo K; Kaelin WG
Exp Cell Res; 2001 Mar; 264(1):117-25. PubMed ID: 11237528
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
Krieg M; Haas R; Brauch H; Acker T; Flamme I; Plate KH
Oncogene; 2000 Nov; 19(48):5435-43. PubMed ID: 11114720
[TBL] [Abstract][Full Text] [Related]
12. [Von Hippel-Lindau disease].
Shuin T; Ashida S; Yao M; Kanno H
Nihon Rinsho; 2000 Jul; 58(7):1448-54. PubMed ID: 10921322
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.
Wiesener MS; Eckardt KU
Nephrol Dial Transplant; 2002 Mar; 17(3):356-9. PubMed ID: 11865075
[No Abstract] [Full Text] [Related]
14. Volatile Hypertensive Crisis Secondary to Pheochromocytoma: A Case Report of von Hippel-Lindau Syndrome.
Anderson S
J Pediatr Health Care; 2020; 34(3):264-272. PubMed ID: 32143938
[No Abstract] [Full Text] [Related]
15. HIF hydroxylation and the mammalian oxygen-sensing pathway.
Safran M; Kaelin WG
J Clin Invest; 2003 Mar; 111(6):779-83. PubMed ID: 12639980
[No Abstract] [Full Text] [Related]
16. Germline mutations in the von Hippel-Lindau (VHL) gene in patients from Poland: disease presentation in patients with deletions of the entire VHL gene.
Cybulski C; Krzystolik K; Murgia A; Górski B; Debniak T; Jakubowska A; Martella M; Kurzawski G; Prost M; Kojder I; Limon J; Nowacki P; Sagan L; Białas B; Kałuza J; Zdunek M; Omulecka A; Jaskólski D; Kostyk E; Koraszewska-Matuszewska B; Haus O; Janiszewska H; Pecold K; Starzycka M; Słomski R; Cwirko M; Sikorski A; Gliniewicz B; Cyryłowski L; Fiszer-Maliszewska Ł; Gronwald J; Tołoczko-Grabarek A; Zajaczek S; Lubiński J
J Med Genet; 2002 Jul; 39(7):E38. PubMed ID: 12114495
[No Abstract] [Full Text] [Related]
17. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A.
Chen F; Slife L; Kishida T; Mulvihill J; Tisherman SE; Zbar B
J Med Genet; 1996 Aug; 33(8):716-7. PubMed ID: 8863170
[TBL] [Abstract][Full Text] [Related]
18. Pediatric pheochromocytoma in association with Von Hippel-Lindau disease: Focus on screening strategies.
Vérot PL; Rabattu PY; Chabre O; Gayot A; Sartelet H; Faguet R; Robert Y; Piolat C
Arch Pediatr; 2020 Nov; 27(8):497-501. PubMed ID: 33067065
[TBL] [Abstract][Full Text] [Related]
19. Cancer. Many vessels, faulty gene.
Kaelin WG
Nature; 1999 May; 399(6733):203-4. PubMed ID: 10353237
[No Abstract] [Full Text] [Related]
20. Bilateral pheochromocytomas and congenital anomalies associated with a de novo germline mutation in the von Hippel-Lindau gene.
Assadi F; Brackbill EL
Am J Kidney Dis; 2003 Jan; 41(1):E3. PubMed ID: 12500216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]